{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:59:28Z","timestamp":1792511968692,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41440-019-0320-9","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T06:03:32Z","timestamp":1567749812000},"page":"1841-1847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?"],"prefix":"10.1038","volume":"42","author":[{"given":"Atsuhisa","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"320_CR1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","volume":"298","author":"J Coresh","year":"2007","unstructured":"Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United State. JAMA. 2007;298:2038\u201347.","journal-title":"JAMA"},{"key":"320_CR2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","volume":"15","author":"DE Weiner","year":"2004","unstructured":"Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004;15:1307\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1681\/ASN.2006101159","volume":"18","author":"A Kottgen","year":"2007","unstructured":"Kottgen A, Russell SD, loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18:1307\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","volume":"41","author":"G Manjunath","year":"2003","unstructured":"Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerosis cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"320_CR5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1053\/j.ajkd.2008.05.030","volume":"52","author":"TY Cheng","year":"2008","unstructured":"Cheng TY, Wen SF, Astor BC, Tao XG, Samet JM, Wen CP. Mortality risks for all causes and cardiovascular diseases and reduced eGFR in a middle-aged working population in Taiwan. Am J Kidney Dis. 2008;52:1051\u201360.","journal-title":"Am J Kidney Dis"},{"key":"320_CR6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/hr.2015.19","volume":"38","author":"A Sato","year":"2015","unstructured":"Sato A. The necessity and effectiveness of mineralocorticoid receptor antagonist in the treatment of diabetic nephropathy. Hyertens Res. 2015;38:367\u201374.","journal-title":"Hyertens Res"},{"key":"320_CR7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/hr.2016.137","volume":"40","author":"S Shibata","year":"2017","unstructured":"Shibata S, Ishizawa K, Uchida S. Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension. Hypertens Res. 2017;40:221\u20135.","journal-title":"Hypertens Res"},{"key":"320_CR8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41440-018-0201-7","volume":"42","author":"M Nishimoto","year":"2019","unstructured":"Nishimoto M, Ohtsu H, Marumo T, Kawarazaki W, Ayuzawa N, Ueda K, et al. Mineralocortiocid receptor blockade suppresses dietary salt-induced ACEI\/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study. Hypertens Res. 2019;42:514\u201321.","journal-title":"Hypertens Res"},{"key":"320_CR9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal failure. N Engl J Med. 2001;345:925\u20136.","journal-title":"N Engl J Med"},{"key":"320_CR10","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829\u201336.","journal-title":"Kidney Int"},{"key":"320_CR11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536\u201342.","journal-title":"Kidney Int"},{"key":"320_CR12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","volume":"21","author":"R Rachmani","year":"2004","unstructured":"Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independentof blood pressure reduction: a randomized controlled study. Diabet Med. 2004;21:471\u20135.","journal-title":"Diabet Med"},{"key":"320_CR13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64\u20138.","journal-title":"Hypertension"},{"key":"320_CR14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A. et al. for The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"320_CR15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. for The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"320_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. for the EMPHASIS-HF Study Group. Eplrerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"320_CR17","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/archinte.168.20.2212","volume":"168","author":"DE Rifkin","year":"2008","unstructured":"Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med. 2008;168:2212\u20138.","journal-title":"Arch Intern Med"},{"key":"320_CR18","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1681\/ASN.2009010025","volume":"20","author":"K Matsushita","year":"2009","unstructured":"Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Change inestimated GFR association with coronary heart disease and mortality. J Am Soc Nephrol. 2009;20:2617\u201324.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/ajh\/hpx223","volume":"31","author":"JI Barzilay","year":"2018","unstructured":"Barzilay JI, Davis B, Pressel SL, Ghosh A, Rahman M, Einhorn PT, et al. The effects of eGFR change on CVD, renal, and mortality outcomes in a hypertensive cohoert treated with 3 different antihypertensive medications. Am J Hypertens. 2018;31:609\u201314.","journal-title":"Am J Hypertens"},{"key":"320_CR20","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1681\/ASN.2009121210","volume":"21","author":"Z Al-Aly","year":"2010","unstructured":"Al-Aly Z, Zeringue A, Fu J, Rauchman MI, McDonald JR, El-Achkar TM, et al. Rate of kidney function decline associates with mortality. J Am Soc Nephrol. 2010;21:1961\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.kint.2016.09.038","volume":"91","author":"CM Clase","year":"2017","unstructured":"Clase CM, Barzillay J, Gao P, Smyth A, Schmieder RE, Tobe S, et al. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcome. Kidney Int. 2017;91:683\u201390.","journal-title":"Kidney Int"},{"key":"320_CR22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJL, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease on long-term renal function. Kidney Int. 2011;80:282\u20137.","journal-title":"Kidney Int"},{"key":"320_CR23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","volume":"51","author":"AJ Apperloo","year":"1997","unstructured":"Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int. 1997;51:793\u20137.","journal-title":"Kidney Int"},{"key":"320_CR24","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/ki.1995.238","volume":"47","author":"HP Hansen","year":"1995","unstructured":"Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving HH. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int. 1995;47:1726\u201331.","journal-title":"Kidney Int"},{"key":"320_CR25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-asociated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685\u201393.","journal-title":"Arch Intern Med"},{"key":"320_CR26","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"JT Wright Jr.","year":"2002","unstructured":"Wright JT Jr., Bakris G, Green T, Agodoa LY, Appel LJ, Charleston J, et al. African American Study of Kidney Disease and Hypertension Study Group: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the ASSK trial. JAMA. 2002;288:2421\u201331.","journal-title":"JAMA"},{"key":"320_CR27","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/HYPERTENSIONAHA.118.11944","volume":"72","author":"D Collard","year":"2018","unstructured":"Collard D, Brouwer TF, Oeters RJG, Vogt L, van den Born BJH. Creatinine rise during blood pressure therapy and the risk of adverse clinical outcomes in patients with type 2 diabetes mellitus. A post hoc analysis of the ACCORD-BP randomized controlled trial. Hypertension. 2018;72:1337\u201344.","journal-title":"Hypertension"},{"key":"320_CR28","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1681\/ASN.2017010040","volume":"28","author":"E Ku","year":"2017","unstructured":"Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, et al. Acute declines in renal function during intensive BP lowering: implications for future ESRD risk. J Am Soc Nephrol. 2017;28:2794\u2013801.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR29","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","volume":"28","author":"AK Cheung","year":"2017","unstructured":"Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. for the SPRINT Research Group. Effects of intensive BP control in CKD. J Am Soc Nephrol. 2017;28:2812\u201323.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR30","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"320_CR31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. for the EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"320_CR32","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","volume":"5","author":"DZI Cherney","year":"2017","unstructured":"Cherney DZI, Zinman B, Inzucchi S, Koitka-Weber A, Mattheus M, von Eynatten M, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from EMPA-REG OUTCOME randomized, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:610\u201321.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"320_CR33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomized clinical trials. Lancet Diabetes Endocrinol. 2018;6:691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"320_CR34","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","volume":"138","author":"BL Neuen","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Cariovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138:1537\u201350.","journal-title":"Circulation"},{"key":"320_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, et al. on behalf of the EMPA-REG OUTCOME investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119\u201329.","journal-title":"Circulation"},{"key":"320_CR36","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2337\/dc11-2189","volume":"35","author":"P Ruggenenti","year":"2012","unstructured":"Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, et al. for the GFR Study Investigators. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012;35:2061\u20138.","journal-title":"Diabetes Care"},{"key":"320_CR37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.me.39.020188.001331","volume":"39","author":"S Anderson","year":"1988","unstructured":"Anderson S, Brenner BM. Intraglomerular hypertension: implications and drug treatment. Annu Rev Med. 1988;39:243\u201353.","journal-title":"Annu Rev Med"},{"key":"320_CR38","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","volume":"57","author":"M Strtic","year":"2014","unstructured":"Strtic M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014;57:2599\u2013602.","journal-title":"Diabetologia"},{"key":"320_CR39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, et al. Renal hemodynamics effect of sodium-glucose cotransporter-2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587\u201397.","journal-title":"Circulation"},{"key":"320_CR40","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jdiacomp.2018.04.011","volume":"32","author":"A Mima","year":"2018","unstructured":"Mima A. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complicat. 2018;32:720\u20135.","journal-title":"J Diabetes Complicat"},{"key":"320_CR41","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00125-010-1794-9","volume":"53","author":"G Jerums","year":"2010","unstructured":"Jerums G, Premaratne E, Panagiotopoulos P, Maclsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53:2093\u20132014.","journal-title":"Diabetologia"},{"key":"320_CR42","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ki.1997.463","volume":"52","author":"PK Christensen","year":"1997","unstructured":"Christensen PK, Hansen HP, Parving HH. Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int. 1997;52:1369\u201374.","journal-title":"Kidney Int"},{"key":"320_CR43","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","volume":"16","author":"J Ribstein","year":"2005","unstructured":"Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16:1320\u20135.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP, Bermini G, Desideri G, et al. PAPY Study Participants. Renal damage in primary aldosteronism; results of the PAPY study. Hypertension. 2006;48:232\u20138.","journal-title":"Hypertension"},{"key":"320_CR45","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","volume":"94","author":"M Reincke","year":"2009","unstructured":"Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab. 2009;94:869\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"320_CR46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2369-15-44","volume":"15","author":"A Hannemann","year":"2014","unstructured":"Hannemann A, Rettig R, Dittmann K, Volzke H, Endlich K, Nauck M, et al. Aldosterone and glomerular filtration-observations in the general population. BMC Nephrol. 2014;15:44.","journal-title":"BMC Nephrol"},{"key":"320_CR47","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.ASN.0000083982.74108.54","volume":"14","author":"S Arima","year":"2003","unstructured":"Arima S, Kohaguro K, Xu HL, Sugawara A, Abe T, Satoh F, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol. 2003;14:2255\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"320_CR48","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1172\/JCI111349","volume":"73","author":"LD Dworkin","year":"1984","unstructured":"Dworkin LD, Hosrerrer TH, Rennke HG, Brenner BM. Hemodynamic basis for glomerular injury in rats with deoxycorticosterone-salt hypertension. J Clin Invest. 1984;73:1448\u201361.","journal-title":"J Clin Invest"},{"key":"320_CR49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.mce.2011.11.026","volume":"350","author":"JW Funder","year":"2012","unstructured":"Funder JW. Aldosterone and mineralocorticoid receptors: A personal reflection. Mol Cell Endcrinol. 2012;350:146\u201350.","journal-title":"Mol Cell Endcrinol"},{"key":"320_CR50","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116\u201323.","journal-title":"Kidney Int"},{"key":"320_CR51","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1001\/jama.295.22.2638","volume":"295","author":"LA Sechi","year":"2006","unstructured":"Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2635\u201345.","journal-title":"JAMA"},{"key":"320_CR52","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","volume":"16","author":"A Sato","year":"2003","unstructured":"Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003;16:781\u20138.","journal-title":"Am J Hypertens"},{"key":"320_CR53","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedk","year":"2004","unstructured":"Schjoedk KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47:1936\u20139.","journal-title":"Diabetologia"},{"key":"320_CR54","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"K Ando","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, for the EVALUATE Study Group. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomized, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:944\u201353.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"320_CR55","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","volume":"302","author":"NM Albert","year":"2009","unstructured":"Albert NM, Yancy CW, Liant L, Zhao X, Hernandez AF, Peterson ED, et al. Use of aldosterone antagonists in heart failure. JAMA. 2009;302:1658\u201365.","journal-title":"JAMA"},{"key":"320_CR56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","volume":"125","author":"P Rossignol","year":"2012","unstructured":"Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone post-acute myocardial infarction heart failure effeicacy and survival study. Circulation. 2012;125:271\u20139.","journal-title":"Circulation"},{"key":"320_CR57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy. Results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7:51\u20138.","journal-title":"Circ Heart Fail"},{"key":"320_CR58","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"R Eschalier","year":"2013","unstructured":"Eschalier R, McMurray JJV, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, et al. for the EMPHASIS-HF Investigators. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function. J Am Coll Cardiol. 2013;62:1585\u201393.","journal-title":"J Am Coll Cardiol"},{"key":"320_CR59","volume":"15","author":"NR Hill","year":"2014","unstructured":"Hill NR, Lasserson D, Thompson B, Perera-Salazar R, Wolstenholme J, Bower P, et al. Benefits of aldosterone receptor antagonism in chronic kidney disease (BARACK D) trial-a multi-centre, prospective, randomized, open, blinded end-point, 36-month study of 2,616 patients with primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25\u2009mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials. 2014;15:160.","journal-title":"Trials"},{"key":"320_CR60","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"KI Birkeland","year":"2017","unstructured":"Birkeland KI, J\u00f8rgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 2017;5:709\u201317.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0320-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-019-0320-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:21:22Z","timestamp":1684617682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-019-0320-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1038\/s41440-019-0320-9","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"9 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declare that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}